bluebird bio To Host A Conference Call To Discuss Initial Results From The HGB-205 Study In Beta-Thalassemia Major Subjects

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced it was hosting a conference call to review the initial results from the HGB-205 Study to be presented on Saturday June 14, 2014 at 04:15 pm CET (10.15 am EDT) at the 19th Annual Congress of the European Hematology Association (EHA) in Milan, Italy.

Help employers find you! Check out all the jobs and post your resume.